Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. - Wikidata - wikimedia - TriplyDB

Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.

Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.

http://www.wikidata.org/entity/Q37243665

about

Is lipid signaling through cannabinoid 2 receptors part of a protective system?Cardiovascular dysfunction in patients with liver cirrhosis Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.Modulating the endocannabinoid system in human health and disease--successes and failures Vascular stasis, intestinal hemorrhage, and heightened vascular permeability complicate acute portal hypertension in cd39-null mice.Cardiovascular changes in cirrhosis: pathogenesis and clinical implications.Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects Cirrhotic Multiorgan Syndrome.

P2860

Q24633122-40F0805D-CAB6-467C-BA24-31351E8CE174 Q27010592-06842598-C1D4-489B-BCC6-70B60FAE368A Q34550846-3BEDBF08-B107-4A57-978A-7388192D52CF Q35228889-9472AB08-8089-492D-B38E-B6DBE4E0E12A Q36933683-19A66143-D40A-4C2A-AE48-8ED83F4BF279 Q37297986-7B79B792-EDCA-4C56-BB37-4672E7D6E386 Q37771146-5BCB0C96-C628-47CF-945D-B34E7BD4E5D2 Q38268612-2B47045A-0BD1-4C56-BA1A-8098FEE04B47 Q38538183-00263878-C2F3-410D-9463-496D1ABBFB79

P2860

Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.

http://www.wikidata.org/entity/Q37243665

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 August 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Endocannabinoids and liver dis ...... ac abnormalities in cirrhosis.

@en

Endocannabinoids and liver dis ...... ac abnormalities in cirrhosis.

@nl

type

label

Endocannabinoids and liver dis ...... ac abnormalities in cirrhosis.

@en

Endocannabinoids and liver dis ...... ac abnormalities in cirrhosis.

@nl

prefLabel

Endocannabinoids and liver dis ...... ac abnormalities in cirrhosis.

@en

Endocannabinoids and liver dis ...... ac abnormalities in cirrhosis.

@nl

P1433

Q37243665-3BC0D8F6-AE42-4B17-B75F-930CEF5F6F4C

P1476

Q37243665-A74C2D08-DA0A-42AD-82F9-CEEABEAB4920

P2093

Q37243665-7373DEE4-8A9B-49FE-AC00-FDF4A2159500

Q37243665-774EC4BF-A580-4F63-AABD-0347EB497498

P2860

Q37243665-0167E862-4A51-4DB4-8363-ECEC7E02FCB5

Q37243665-08BC386F-73BE-4744-A3C2-34E531DD7EFB

Q37243665-13E26E3B-00C1-4CD4-B751-A59BFC9F7F02

Q37243665-25E6B4FC-25F0-4A6E-8EAD-EC60071F9684

Q37243665-2F440070-BD1B-45D3-96FB-C0E893163F7D

Q37243665-340B65D5-8B40-4A9E-9012-FB79CC30230F

Q37243665-4A164E5B-CB05-4732-98C0-4D7A0A6269E1

Q37243665-76E3424D-5D87-42F6-A454-BA048CACA7C7

Q37243665-84D55959-B572-4E47-8376-AAF24D0DD952

Q37243665-8B831D11-B461-438F-8075-D6B7EE119AB6

P304

Q37243665-9304F42A-EBEC-4B9C-AC67-AC2CB59C6161

P31

Q37243665-5fc07f72-458a-4010-8205-cd0286f9fa2e

Q37243665-744C63E2-E494-4786-9DE6-D9A32552BFD3

P356

Q37243665-44D2556D-09BA-4674-B8F0-24B5C1360A7E

P433

Q37243665-75CCFC0B-CEB5-48A2-806B-A90400F89517

P478

Q37243665-8A3B3772-DCF9-4C38-86FC-FD8403CA5485

P50

Q37243665-6BB248E1-CCBA-4C91-BBB1-E2F357BCF5C5

P577

Q37243665-1D383605-B8D2-405B-BB2D-F85482208DE7

P5875

Q37243665-1C30C817-C7F9-4015-9B68-125E93A25C9C

P698

Q37243665-78C443DD-7618-40D6-823F-B947764031F1

P921

Q37243665-1EE81803-0CEA-45BF-B721-03C625FE9F7D

Q37243665-E277B74C-5EC1-4BED-8FC1-ACAF527D9CA4

P356

AJPGI.90352.2008

P1433

American Journal of Physiology - Gastrointestinal and Liver Physiology

P1476

Endocannabinoids and liver dis ...... iac abnormalities in cirrhosis

@en

P2093

Samuel S Lee

http://www.w3.org/2001/XMLSchema#string

Seyed Ali Gaskari

http://www.w3.org/2001/XMLSchema#string

P2860

Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide

The complexities of the cardiovascular actions of cannabinoids

Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase.

Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.

Therapy insight: Cirrhotic cardiomyopathy.

Interactions between synthetic vanilloids and the endogenous cannabinoid system.

Cirrhotic cardiomyopathy: getting to the heart of the matter.

Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.

Hepatic venous dysregulation contributes to blood volume pooling in cirrhotic rats.

Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts.

P304

G649-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPGI.90352.2008

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

295

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23171331

http://www.w3.org/2001/XMLSchema#string

P698

18703639

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

endocannabinoids